Gilead Submits NDA for HIV Combo

Jun 15, 2017

Nasdaq

Gilead Sciences has filed a new drug application with the FDA for a once-daily combo tablet as a treatment for adult patients with HIV-1 infection.

The investigational single tablet regimen contains bictegravir and emtricitabine/tenofovir alafenamide. The NDA is supported by encouraging data from four phase III studies in which the regimen met its primary objective of non-inferiority.

Gilead will go head-to-head with GlaxoSmithKline with rival versions of this improved class of HIV medicines.

Read the Nasdaq coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments